NANOVIRICIDES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
NANOVIRICIDES, INC. (NNVC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of $0 for the 12-month period ending 2020-06-30, per its 10-K filed 2021-10-12.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2021-10-12
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2020-06-30 was -$5.85M.
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2020-03-31 was $6.12M.
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2019-12-31 was $147.08K.
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2019-09-30 was -$421.53K.
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2020 was $0.00.
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2019 was $0.00.
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2017 was -$819.99K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2020-06-30 | -$5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-12 | $274.45K derived: sum of 2 quarters · filed 2021-10-12 | $421.53K derived: sum of 3 quarters · filed 2021-10-12 | $0.00 10-K · filed 2021-10-12 |
| 2020-03-31 | $6.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-22 | $6.27M derived: sum of 2 quarters · filed 2020-06-22 | $5.85M 10-Q · filed 2020-06-22 | |
| 2019-12-31 | $147.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-14 | -$274.45K 10-Q · filed 2020-02-14 | ||
| 2019-09-30 | -$421.53K 10-Q · filed 2019-11-15 | |||
| 2019-06-30 | $0.00 10-K · filed 2020-10-13 | |||
| 2017-12-31 | $701.14K 10-Q · filed 2018-02-20 | -$701.14K 10-Q · filed 2018-02-20 | ||
| 2017-06-30 | -$819.99K 10-K · filed 2020-10-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |